Recurrent Pericarditis
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceDiscussion
No takes yet. Share an insight, caveat, or question.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The emergence of advanced imaging — including echo as well as CMR — as a comprehensive diagnostic and monitoring tool and the addition of IL-1 blockers to the treatment armamentarium have significantly changed our ability to manage this very difficult condition.”
“Rilonacept represents a new targeted approach to recurrent pericarditis. Results of this pivotal study indicate this type of interleukin-1 blocker may be a game changer in the management of patients with this disease.”
“There are no American clinical guidelines on this topic, and the latest European guidelines were published in 2015, before clinical trials of interleukin-1 blockers in recurrent pericarditis were conducted. This document informs best practices with the goal of reducing variability in the evaluation and management of these patients.”
Cite This Study
Klein et al. (2023) studied this question.